-
Prostate Cancer Standardized Diagnosis and Treatment Courses——Full-process Standardized Management of Prostate Cancer
Time of Update: 2021-03-27
The fifth "Prostate Cancer Standardized Diagnosis and Treatment Course", the fifth is the "Full-process Standardized Management of Prostate Cancer" brought by Professor Guo Gang from the PLA General Hospital: Click to watch the highlights video!
-
[Phase 2] Standardized Diagnosis and Treatment Courses for Prostate Cancer——Strategies of Endocrine Therapy for Prostate Cancer
Time of Update: 2021-03-25
The second phase of "Prostate Cancer Standardized Diagnosis and Treatment Course" The second phase is "Strategies for Endocrine Therapy of Prostate Cancer" brought by Professor Dai Bo from Fudan University Affiliated Cancer Hospital: Click to watch the highlights video!
-
[Phase 1] Standardized Diagnosis and Treatment Course for Prostate Cancer-Screening and Early Diagnosis of Prostate Cancer
Time of Update: 2021-03-25
The first phase of "Prostate Cancer Standardized Diagnosis and Treatment Course" Phase 1 is the "Screening and Early Diagnosis of Prostate Cancer" by Professor Zeng Yu from Liaoning Cancer Hospital: Click to watch the highlights video!
-
Express | A new generation of antibody-conjugated drugs obtained priority review by the FDA, Qilu Pharmaceutical has development rights in Greater China
Time of Update: 2021-03-25
In July last year, Qilu Pharmaceutical and Sesen Bio reached an exclusive license agreement to obtain Vicineum's exclusive development rights in Greater China for the treatment of non-muscle invasive bladder cancer and other cancer types that did not respond to Bacille Calmette-Guerin (BCG).
-
Express | Significantly improve the overall survival of bladder cancer patients, "first-in-class" antibody-conjugated drug Phase 3 clinical results released
Time of Update: 2021-03-25
▎The content team editor of WuXi AppTec recently, Seagen (formerly Seattle Genetics) and Astellas Pharma jointly announced an innovative antibody conjugate drug Padcev (enfortumab vedotin-ejfv) to treat locally advanced or metastatic urothelial cancer The patient's Phase 3 clinical trial results were published in the New England Journal of Medicine (NEJM).
-
Express | Complete remission rate reached 71%, IL-15 super agonist reached phase 2/3 clinical endpoint
Time of Update: 2021-03-25
▎The editor of WuXi AppTec's content team announced today that its IL-15 super agonist complex Anktiva (N-803) combined with BCG vaccine (BCG) can be used in the treatment of non-muscle invasive bladder cancer that does not respond well to BCG (NMIBC) The primary endpoint was reached in the Phase 2/3 clinical phase of Carcinoma in Situ (CIS).
-
"Where to go" for bladder outlet obstruction in patients with benign prostatic hyperplasia?
Time of Update: 2021-03-25
By blocking the binding of α1A adrenergic receptors and norepinephrine, Serodosin relaxes the smooth muscles of the bladder and prostate, relieves bladder outlet dynamic obstruction, and effectively improves lower urinary tract symptoms caused by BPH4.
-
BMJ Open: High coffee intake may be linked to low prostate cancer risk
Time of Update: 2021-03-25
Recently, a new paper published on BMJ Open conducted a meta-analysis of these cohort studies and systematically reviewed the relationship between coffee intake and prostate cancer risk.
-
2020 ASCO GU | Summary Express Session: New Advances in Prostate Cancer Immunotherapy
Time of Update: 2021-03-25
The previous data of cohort B (at a median follow-up of 20 months) showed that pembrolizumab + docetaxel + prednisone showed good results in mCRPC patients who were previously treated with abiraterone or enzalutamide.
-
2021 ASCO GU | Professor Sheng Xinan's interpretation: Research progress of upper urinary tract urothelial cancer
Time of Update: 2021-03-25
Coincidentally, another team on ASCO-GU this year published a small-sample clinical retrospective study that specifically analyzed the results of ICI treatment for dMMR/MSI UTUC patients.
Excluding the patient population with special molecular expressions, this year there is also a large-sample retrospective study to analyze the ICI efficacy of UTUC and LTUC from the overall level.
-
Prof. Bangmin Han: Measuring the comprehensive benefits of first-line treatment for CRPC patients
Time of Update: 2021-03-25
A retrospective study analyzed data from the Veterans Health Administration (VA) database and included 3637 patients diagnosed with mCRPC from January 2006 to August 2015, and evaluated Epoch1 (from 2006 to 2010, 83% of patients were first-line The treatment was docetaxel chemotherapy) and Epoch2 (from 2011 to 2016, 62% of patients were treated with enzalutamide or abiraterone as first-line treatment) time to biochemical progression and OS.
-
Urine spermine and multivariate spermine risk score can predict high-grade prostate cancer
Time of Update: 2021-03-25
Recently, researchers have investigated the role of urine spermine and spermine risk scores in predicting high-grade prostate cancer (HGPCa, ISUP grade group ≥ 2).
Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer.
-
Explore the "Secret" Archives File008 | Do not wear pants section, dare to break your bottom line?
Time of Update: 2021-03-25
*Only for medical professionals to read and refer to the strange and weird knowledge adds to the wonderful review of the past ☑ Explore the "Secret" Archives File001 | The unsolved mystery of the relationship between testosterone and prostate cancer ☑ Explore the "Secret" Archives File002 | Young Why is the prognosis worse for women with breast cancer?
-
2021 ASCO GU | EV-201 Study Cohort 2 study results announced!
Time of Update: 2021-03-25
Conclusion: In the EV-201 study cohort 2, most of the patients with PD-1/L1 inhibitors who were not suitable for cisplatin and did not receive platinum-based treatment of la/mUC who had progressed in the treatment of the EV-201 had a long-lasting response to EV, including 1 Out of 5 patients achieved CR, the results of PFS and OS are encouraging.
-
Professor Wei Yu: Progress in China's Prostate Cancer Research in 2020
Time of Update: 2021-03-25
Sun Yinghao, Shanghai Changhai Hospital, published a study in European Journal of Cancer: Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.
-
Express | Reduce the risk of death by 35%, the final results of Janssen's phase 3 prostate cancer therapy are released
Time of Update: 2021-03-25
The results of the trial showed that in patients with metastatic castration-sensitive prostate cancer (mCSPC), the addition of Erleada to androgen deprivation therapy (ADT) significantly improved the overall survival (OS) of patients compared with placebo.
-
make a prompt decision!
Time of Update: 2021-03-25
A high-risk mHSPC patient with hypertension and multiple bone metastases received long-term treatment with apatamide + ADT, which has a significant effect and is expected to achieve long-term high-quality survival.
-
2021 ASCO GU | Inventory of major research in the field of prostate cancer treatment
Time of Update: 2021-03-25
The ACIS study compared the imaging progression-free survival (rPFS) of mCRPC patients treated with apatamide or placebo + abiraterone acetate + prednisone without chemotherapy.
02 Abstract Express Special TITAN Study Final Analysis Results Background: The TITAN study evaluated the efficacy and safety of apatamide versus placebo for metastatic castration-sensitive prostate cancer (mCSPC).
-
Nature Cell Biology: Single cell analysis reveals the mechanism of human prostate cancer progression
Time of Update: 2021-03-25
Recently, researchers have analyzed the transcriptomes of 36,424 single cells from 13 types of prostate tumors and identified epithelial cells to explain the underlying disease invasion mechanism.
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression.
-
Wei Qiang, Professor TOMBAL: Frontiers of Clinical Data and Practice of Enzalutamide
Time of Update: 2021-03-25
The approval of the indication for enzalutamide nmCRPC marks a major progress in this devastating disease, and provides a new and meaningful treatment option for doctors and patients with castration-resistant prostate cancer (CRPC).
